Kailera Reports Late-Stage Trial Data for Oral GLP-1 Drug
Shares of Kailera Therapeutics (KLRA) fell over 10% after the company released top-line data from two late-stage trials in China for its oral GLP-1 drug candidate HRS-7535. The results did not meet expectations, leading to a significant drop in stock price.
Tickers: $KLRA
Topics: Biotech GLP-1 Drugs Stock Movement